

Studies on new tumour active compounds with one or more metal centres

Hasan Tayyem

*A thesis submitted in fulfilment of the requirements for the
degree of
Doctor of Philosophy*

School of Biomedical Sciences
Faculty of Health Sciences
University of Sydney, Australia



September, 2006

Certification by the Supervisor

I certify that the thesis entitled: “Studies on new tumour active compounds with one or more metal centres” submitted by Hasan Tayyem for the Degree of Doctor of Philosophy of The University of Sydney is ready for examination.

Fazlul Huq

Declaration

I, the author of the thesis, declare that none of the material in this thesis has been previously submitted by me or any other candidate for any degree to this or any other university.

Hasan Tayyem

Acknowledgement

I thank Almighty God for granting me strength, wisdom, confidence and perseverance to carry out my studies. Without His grace and mercy, I would not have been able to complete this study.

There are a number of people who have helped me during the course of my research; however, it is impossible to record all of them here. I hope that they accept my sincere thanks and appreciation. I find myself deeply indebted to some people that I have to mention their names.

My deepest gratitude goes to my parents who gave me their unconditional support from miles away and patiently anticipated successful completion of my study. To repay the debt of the parents is impossible; it is even truer for me

I would like to express my respect and sincere gratitude to my supervisor, Dr Fazlul Huq, for his expert guidance, constructive criticism and continuous support and encouragement throughout my study. It has been a privilege to work with him. His assistance and friendship will always be remembered

I would like to thank my associate supervisor, Dr. Philip Beale for his valuable suggestion and comments throughout the period of my candidature.

I am also grateful to all my colleagues: Dr. Hassan Dagherri, Dr. Jun Qing Yu, Dr. Howard Cheng, Dr. Ahmed Abdullah, Ali Alshehri, Mohammad Farhad, Jihad Al-Shuneigat, Mariam Farhad, Narjes Deqnah, Deena Ababneh, Shahnaz Al-qassab and Noorhanan Murni Yunos, for their help, support and friendship.

I am greatly indebted to my brother Dr Waleed and his family for their kindness, assistance, compassion and care of my family during my study. I would also like to thank my other brothers, Abdel-Kareem, Khaleed and Issam and my sisters, Zohra, Reema, Manal and Kulud for their support and encouragement.

Finally, all my love goes to my wife Randa. I cherish her love, care, understanding and patience. Her unwavering encouragement has meant so much during the course of my PhD candidature. Also, one of the happiest experiences during the period of the candidature has been the birth of our lovely daughter 'Lara' who has been a source of constant joy for my wife and me.

Contents

| | |
|--|-----|
| Abstract | XII |
| Abbreviations..... | XIV |
| List of Figures..... | XVI |
| List of Tables | XX |
| Chapter One | 1 |
| 1 Literature review | 1 |
| 1.1 Cancer | 1 |
| 1.1.1 Causes of cancer | 2 |
| 1.1.1.1 Smoking..... | 2 |
| 1.1.1.2 Diet..... | 3 |
| 1.1.1.3 Obesity..... | 3 |
| 1.1.1.4 Infection..... | 4 |
| 1.1.2 The cell cycle division..... | 4 |
| 1.1.2.1 Cell cycle and checkpoints | 6 |
| 1.1.2.2 Cancerous growth and body functions | 7 |
| 1.1.3 Genes involved in cancer | 8 |
| 1.1.3.1 Proto-oncogenes..... | 8 |
| 1.1.3.2 Tumour suppressor genes | 8 |
| 1.1.3.3 Cell cycle regulator genes..... | 9 |
| 1.1.3.4 Drug resistance and susceptibility genes..... | 9 |
| 1.2 Ovarian cancer..... | 9 |
| 1.2.1 Epidemiology of ovarian cancer | 11 |
| 1.2.2 Causes of ovarian cancer | 11 |
| 1.2.2.1 Genetic factor..... | 12 |
| 1.2.2.2 Environmental factors | 14 |
| 1.2.3 Surgery of advanced ovarian cancer | 15 |
| 1.3 DNA structure and conformation | 17 |
| 1.3.1 Structure of DNA | 17 |
| 1.3.2 Conformational form of DNA | 20 |
| 1.4 Treatment of cancer | 22 |
| 1.4.1 Radiation oncology (Radioisotopes and Radiotherapy)..... | 23 |

| | | |
|-------------|---|----|
| 1.4.2 | Surgery | 24 |
| 1.4.3 | Chemotherapy | 25 |
| Chapter Two | | 27 |
| 2 | Cisplatin and other platinum drugs..... | 27 |
| 2.1 | First generation drugs | 27 |
| 2.1.1 | Cisplatin..... | 27 |
| 2.1.1.1 | Platinum and chemistry of cisplatin..... | 28 |
| 2.1.1.2 | Labile and non-labile ligands in cisplatin..... | 29 |
| 2.1.1.3 | Side-Effects of cisplatin | 31 |
| 2.1.1.4 | Formation of DNA covalent adducts | 32 |
| 2.1.1.5 | Kinetic behaviour of cisplatin in aqueous solution..... | 33 |
| 2.1.2 | Transplatin..... | 35 |
| 2.1.2.1 | More about the difference between cisplatin and transplatin | 36 |
| 2.2 | Second- and third-generation drugs..... | 37 |
| 2.2.1 | Second-generation drugs | 38 |
| 2.2.1.1 | Carboplatin | 38 |
| 2.2.1.2 | Nedaplatin..... | 40 |
| 2.2.1.3 | Iproplatin | 40 |
| 2.2.2 | Third-generation drugs..... | 41 |
| 2.2.2.1 | Oxaliplatin (Eloxatine) | 41 |
| 2.2.2.2 | JM216 (Satraplatin) and JM118..... | 43 |
| 2.2.2.3 | Lobaplatin | 44 |
| 2.2.2.4 | ZD0473..... | 45 |
| 2.2.2.5 | C5-OHP-Cl | 46 |
| 2.3 | Dinuclear and trinuclear compounds | 48 |
| 2.3.1 | More on DNA binding of multi-nuclear platinum complexes | 52 |
| 2.3.2 | BBR3464 | 53 |
| 2.3.2.1 | Binding of BBR3464 to DNA | 55 |
| 2.4 | Tumour active compounds of other metals..... | 56 |
| 2.5 | Mechanisms of cisplatin resistance | 60 |
| 2.5.1 | Cell uptake and efflux of cisplatin..... | 61 |
| 2.5.2 | Decreased apoptosis | 63 |
| 2.5.3 | Inactivation of cisplatin by sulfur-containing molecules | 65 |
| 2.5.4 | Enhanced DNA repair | 66 |

| | | |
|---------------|--|-----|
| 2.5.4.1 | Nucleotide excision repair (NER)..... | 66 |
| 2.5.4.2 | Mismatch repair | 69 |
| 2.6 | Drug resistance due to deactivation..... | 71 |
| 2.6.1 | Glutathione | 71 |
| 2.6.2 | Metallothioneins | 72 |
| 2.7 | Present study..... | 73 |
| Chapter Three | | 78 |
| 3 | Materials and Methods..... | 78 |
| 3.1 | Introduction | 78 |
| 3.2 | Synthesis of the compounds..... | 78 |
| 3.2.1 | Materials used..... | 78 |
| 3.2.2 | Preparation of cisplatin and transplatin..... | 79 |
| 3.2.2.1 | Preparation of cisplatin..... | 79 |
| 3.2.2.2 | Preparation of transplatin..... | 80 |
| 3.2.3 | Syntheses of mononuclear compounds | 81 |
| 3.2.3.1 | Preparation of trans-PtCl ₂ (3-hydroxypyridine) ₂ [CH1] | 81 |
| 3.2.3.2 | Preparation of trans-PdCl ₂ (3-hydroxypyridine) ₂ [TH5] | 82 |
| 3.2.3.3 | Preparation of trans-PdCl ₂ (2-hydroxypyridine) ₂ [TH6]..... | 83 |
| 3.2.3.4 | Preparation of trans-PdCl ₂ (4-hydroxypyridine) ₂ [TH7]..... | 84 |
| 3.2.4 | Syntheses of trinuclear compounds | 85 |
| 3.2.4.1 | Preparation of [{trans-PtCl(NH ₃) ₂ } ₂ μ- {trans-Pt(3-hydroxypyridine) ₂ (H ₂ N (CH ₂) ₆ NH ₂) ₂ }]Cl ₄ (TH1) | 86 |
| 3.2.4.2 | Preparation of [{trans-PtCl(NH ₃) ₂ } ₂ μ- {trans-Pd(4-hydroxypyridine) ₂ (H ₂ N (CH ₂) ₆ NH ₂) ₂ }]Cl ₄ (TH8)..... | 89 |
| 3.2.4.3 | Preparation of [{trans-PtCl(NH ₃) ₂ } ₂ μ- {trans-Pt(3-hydroxypyridine) ₂ (H ₂ N (CH ₂) ₄ NH ₂) ₂ }]Cl ₄ (TH14) | 92 |
| 3.3 | Characterization of compounds..... | 95 |
| 3.3.1 | Microanalysis..... | 95 |
| 3.3.2 | Preparation standard solution for A.A.S. | 96 |
| 3.3.2.1 | Platinum standard solution | 96 |
| 3.3.2.2 | Palladium standard solution..... | 96 |
| 3.3.3 | Calculating percentage yield of the compound | 103 |
| 3.3.4 | Molar conductivity..... | 103 |
| 3.3.5 | Spectral studies | 104 |

| | | |
|----------|---|-----|
| 3.3.5.1 | Infrared spectra | 104 |
| 3.3.5.2 | Mass spectrometry | 105 |
| 3.3.5.3 | Nuclear magnetic resonance spectroscopy (NMR)..... | 105 |
| 3.4 | Biological activity..... | 107 |
| 3.4.1 | Introduction of tissue culture | 107 |
| 3.4.2 | Materials | 108 |
| 3.4.3 | Maintenance of the cell lines | 109 |
| 3.4.4 | Preparation of the medium | 110 |
| 3.4.5 | Phosphate buffered saline (PBS) | 111 |
| 3.4.5.1 | Materials | 111 |
| 3.4.5.2 | Procedure | 111 |
| 3.4.6 | Trypsin | 111 |
| 3.4.7 | HEPES..... | 112 |
| 3.4.8 | Cells recovery from liquid nitrogen..... | 112 |
| 3.4.9 | Cell subculture | 113 |
| 3.4.9.1 | Procedure | 113 |
| 3.4.10 | Cell count..... | 114 |
| 3.4.11 | Storage of the cell lines | 115 |
| 3.4.12 | MTT-Based cytotoxicity assay | 115 |
| 3.4.12.1 | Introduction to cytotoxicity | 115 |
| 3.4.12.2 | MTT cell viability assay | 116 |
| 3.4.12.3 | Methods | 117 |
| 3.5 | Cellular platinum uptakes and DNA binding..... | 118 |
| 3.5.1 | Materials | 118 |
| 3.5.2 | Cell uptake..... | 119 |
| 3.5.3 | Platinum DNA binding..... | 119 |
| 3.6 | Interaction with DNA | 121 |
| 3.6.1 | Introduction | 121 |
| 3.6.2 | Basic principle of gel electrophoresis | 121 |
| 3.6.3 | Factors affecting electrophoresis | 124 |
| 3.6.4 | Materials | 125 |
| 3.6.5 | Preparation of 50X TAE stock solution and working buffers | 126 |
| 3.6.6 | Gel preparation | 126 |
| 3.6.7 | Preparation of ssDNA | 127 |

| | | |
|--------------------|--|-----|
| 3.6.8 | Interaction with ssDNA..... | 127 |
| 3.6.8.1 | Method..... | 127 |
| 3.6.9 | Interaction with pBR322 plasmid DNA..... | 128 |
| 3.6.10 | Interaction with pBR322 plasmid DNA combined with BamH1 | 129 |
| 3.6.10.1 | Methods | 129 |
| 3.7 | Interaction with nucleobases using HPLC | 130 |
| 3.7.1 | Materials..... | 130 |
| 3.7.2 | Methods..... | 131 |
| Chapter Four | | 132 |
| 4 | Results..... | 132 |
| 4.1 | Characterization of compounds..... | 132 |
| 4.1.1 | Characterization of mononuclear complexes | 133 |
| 4.1.1.1 | TH5: trans-PdCl ₂ (3-hydroxypyridine) ₂ | 133 |
| 4.1.1.2 | TH6: trans-PdCl ₂ (2-hydroxypyridine) ₂ | 133 |
| 4.1.1.3 | TH7: trans-PdCl ₂ (4-hydroxypyridine) ₂ | 133 |
| 4.1.2 | Elemental compositions of TH5, TH6 and TH7..... | 134 |
| 4.1.3 | Characterization of the trinuclear compounds..... | 135 |
| 4.1.3.1 | TH1: {trans-PtCl(NH ₃) ₂ } ₂ {trans-Pt(3-hydroxypyridine) ₂ (H ₂ N(CH ₂) ₆ NH ₂) ₂ }Cl ₄ | 135 |
| 4.1.3.2 | TH8: {trans-PtCl(NH ₃) ₂ } ₂ {trans-Pd(4-hydroxypyridine) ₂ (NH ₂ (CH ₂) ₆ NH ₂) ₂ }Cl ₄ | 135 |
| 4.1.3.3 | TH14: {trans-PtCl(NH ₃) ₂ } ₂ {trans-Pt(3-hydroxypyridine) ₂ (H ₂ N(CH ₂) ₄ NH ₂) ₂ }Cl ₄ | 136 |
| 4.1.4 | Elemental compositions of TH1, TH8 and TH14..... | 136 |
| 4.2 | Spectral studies..... | 138 |
| 4.2.1 | IR spectra for TH5, TH6, TH7, TH1, TH8 and TH14..... | 138 |
| 4.2.2 | Mass spectra for TH5, TH6, TH7, TH1, TH8 and TH14..... | 147 |
| 4.2.3 | Nuclear magnetic resonance spectra (¹ H NMR) of TH5, TH6, TH7, TH1, TH8 and TH14 | 155 |
| 4.3 | Molar conductivity..... | 162 |
| 4.4 | Cytotoxicity..... | 164 |
| 4.4.1 | Cytotoxicity of TH5, TH6, TH7 and cisplatin..... | 164 |
| 4.4.2 | Cytotoxicity of TH1, TH8, TH14 and cisplatin..... | 171 |
| 4.4.3 | Activity summary..... | 177 |

| | | |
|--------------------|--|-----|
| 4.5 | Cell uptake and DNA binding | 178 |
| 4.5.1 | Cell uptake..... | 178 |
| 4.5.2 | DNA binding | 187 |
| 4.6 | Gel electrophoresis | 195 |
| 4.6.1 | Interaction between the compounds and ssDNA..... | 196 |
| 4.6.2 | Interaction with pBR322 plasmid DNA..... | 197 |
| 4.6.3 | BamH1 Digestion..... | 200 |
| 4.7 | Interaction with nucleobases (HPLC)..... | 204 |
| 4.7.1 | Binding ratio | 206 |
| Chapter Five..... | | 207 |
| 5 | Discussion | 207 |
| 5.1 | Characterization of compounds..... | 207 |
| 5.2 | Elemental analysis | 208 |
| 5.3 | Spectral analyses..... | 209 |
| 5.3.1 | IR..... | 209 |
| 5.3.2 | Mass spectrum | 212 |
| 5.3.3 | Nuclear magnetic resonance spectroscopy (NMR)..... | 215 |
| 5.4 | Molar conductivity..... | 217 |
| 5.5 | Activity of the compounds | 219 |
| 5.5.1 | Mononuclear compounds (TH5, TH6 and TH7) | 219 |
| 5.5.2 | Trinuclear compounds (TH1, TH8 and TH14)..... | 221 |
| 5.6 | Cell uptake..... | 222 |
| 5.6.1 | Mononuclear compounds (TH5, TH6 and TH7) | 222 |
| 5.6.2 | Trinuclear compounds (TH1, TH8 and TH14)..... | 223 |
| 5.7 | DNA binding | 225 |
| 5.7.1 | Mononuclear compounds (TH5, TH6 and TH7) | 225 |
| 5.7.2 | Trinuclear compounds (TH1, TH8 and TH14)..... | 227 |
| 5.8 | Interaction with ssDNA | 229 |
| 5.9 | Interaction with pBR322 plasmid DNA | 231 |
| 5.10 | BamH1 restriction enzyme digestion..... | 235 |
| 5.11 | Interaction with nucleobases (HPLC)..... | 237 |
| Chapter Six | | 239 |
| 6 | Conclusion | 239 |
| Bibliography | | 245 |

Abstract

The present study deals with the synthesis, characterization, determination of anticancer activity of three mononuclear *trans*-planaraminepalladium(II) complexes code named TH5, TH6 and TH7 and three trinuclear complexes code named TH1, TH8 and TH14. The activity of the compounds against human cancer cell lines: A2780, A2780^{cisR} and A2780^{ZD0473R}, cell uptake, DNA-binding and nature of interaction with pBR322 plasmid DNA have been determined. Whereas cisplatin binds with DNA forming mainly intrastrand GG adduct that causes local bending of a DNA strand, TH5, TH6, TH7, TH1 and TH8 bind with DNA forming mainly interstrand GG adducts that causes more of a global change in DNA conformation. Although TH5, TH6 and TH7 each have two substituted pyridine ligands in a *trans*-geometry (3-hydroxypyridine in TH5, 2-hydroxypyridine in TH6 and 4-hydroxypyridine in TH7), the compounds differ in their activity against ovarian cancer cell lines, indicating that non-covalent interactions involving the hydroxyl group may be playing a significant role in activity of the compounds. Among trinuclear complexes TH1 is found to be significantly more active than cisplatin. It is actually twice as active as cisplatin against the parent cell line A2780, thirteen times as active as cisplatin against the cisplatin-resistant cell line A2780^{cisR} and 11.5 times as active as cisplatin against the cell line A2780^{ZD0473R}. Whereas the resistance factor for cisplatin as applied to the cell lines A2780 and A2780^{cisR} cell lines is 12.9 that for TH1 is 1.98. The results suggest that TH1 has been able to significantly overcome resistance operating in A2780^{cisR} cell line. The compound is soluble in water so that it may be taken orally. Provided it has favourable toxicity profile, TH1 has the potential

to be developed into a highly active anticancer drug with a wider spectrum of activity than cisplatin. Although platinum drugs use a shot-gun approach to kill cancerous cells, widespread use in the clinic and increasing volume of their sale indicate that even in the genomic age, there is still need for shot-gun drugs in the clinic.

Abbreviations

| | |
|------------------|--|
| AAS | Atomic absorption spectrophotometry |
| BBR3464 | $[[\textit{trans}\text{-PtCl}(\text{NH}_3)_2]_2\{\mu\text{-trans}\text{-Pt}(\text{NH}_3)_2(\text{NH}_2(\text{CH}_2)_6\text{NH}_2)_2\}]^{4+}$ |
| C5-OHP-Cl | <i>trans</i> -bis(n-valerato)(1R,2R-cyclohexanediamine)(oxalate)platinum(IV) |
| CBCD | <i>cis</i> -diammine-1,1-cyclobutanedicarboxylateplatinum(II) |
| CDKs | Cyclin-dependent protein kinases |
| CH1 | <i>trans</i> -PtCl ₂ (3-hydroxypyridine) ₂ |
| <i>cis</i> -DDP | Cisplatin |
| DACH | 1,2-diamminocyclohexane |
| DMF | <i>N,N</i> -dimethylformamide |
| DMSO | Dimethyl sulfoxide |
| DNA | Deoxyribonucleic acid |
| DRA | Diffuse reflectance accessory |
| EDTA | Ethylenediaminetetraacetic acid |
| ESI | Electrospray ionization |
| FCS | Fetal calf serum |
| GSH | Glutathione |
| HNPCC | Hereditary nonpolyposis colorectal cancer |
| HPLC | High performance liquid chromatography |
| IC ₅₀ | Concentration required inhibiting cell growth by 50% |
| IR | Infrared |
| JM118 | <i>cis</i> -amminedichloro(cyclohexylamine)platinum(II) |
| JM216 | bis-aceto-amminedichloro-cyclohexylamine-platinum(IV) |
| MMR | Mismatch repair |
| MT | Metallothionein |
| MTT | 3-(4, 5-dimethylthiazol -2-yl)-2, 5-diphenyltetrazolium bromide |
| NER | Nucleotide excision repair |
| NMR | Nuclear magnetic resonance |
| NSCLC | Non-small cell lung cancer |
| PBS | Phosphate buffered saline |
| RF | Resistant factor |
| RNA | Ribonucleic acid |

| | |
|-------------------|--|
| RPMI | Refers to media developed at Roswell Park Memorial Institute |
| SCLC | Small cell lung cancer |
| ssDNA | Salmon Sperm DNA |
| TAE | Tris-acetate EDTA |
| TBE | Tris-borate EDTA |
| TH1 | $[trans\text{-PtCl}(\text{NH}_3)_2]_2\{trans\text{-Pt}(3\text{-hydroxypyridine})_2(\text{H}_2\text{N}(\text{CH}_2)_6\text{NH}_2)_2\}\text{Cl}_4$ |
| TH14 | $[trans\text{-PtCl}(\text{NH}_3)_2]_2\{trans\text{-Pt}(3\text{-hydroxypyridine})_2(\text{H}_2\text{N}(\text{CH}_2)_4\text{NH}_2)_2\}\text{Cl}_4$ |
| TH5 | $trans\text{-PdCl}_2(3\text{-hydroxypyridine})_2$ |
| TH6 | $trans\text{-PdCl}_2(2\text{-hydroxypyridine})_2$ |
| TH7 | $trans\text{-PdCl}_2(4\text{-hydroxypyridine})_2$ |
| TH8 | $[trans\text{-PtCl}(\text{NH}_3)_2]_2\{trans\text{-Pd}(4\text{-hydroxypyridine})_2(\text{H}_2\text{N}(\text{CH}_2)_6\text{NH}_2)_2\}\text{Cl}_4$ |
| TPE | Tris-phosphate EDTA |
| <i>trans</i> -DDP | Transplatin |
| Triton X-100 | t-Octylphenooxypolyethoxyethanol |
| ZD0473 | <i>cis</i> -amminedichloro(2-methylpyridine)platinum(II) |

List of Figures

| | |
|--|----|
| Figure 1.1: The role of specific cyclins and CDKs in the cell cycle..... | 6 |
| Figure 1.2: The cell cycle and checkpoints | 7 |
| Figure 1.3: Schematic diagram showing normal function of the BRCA gene and loss of BRCA function in ovarian cancer. | 13 |
| Figure 1.4: The chemical structure of the nucleotide adenosine diphosphate (ADP) .. | 17 |
| Figure 1.5: The structures of nucleobases found in the DNA. | 18 |
| Figure 1.6: Deoxyribose, which lacks oxygen and its parent compound, ribose | 18 |
| Figure 1.7: The phosphodiester backbone for the sequence d(ACGT)..... | 19 |
| Figure 1.8: Hydrogen bonding interactions between A and T, and between G and C. | 19 |
| Figure 1.9: Three forms of DNA, from left to right, A-DNA, B-DNA, and Z-DNA. . | 20 |
| Figure 2.1: Molecular structures of anticancer drug cisplatin (<i>cis</i> -configurations) and its inactive isomer transplatin (<i>trans</i> -configurations)..... | 29 |
| Figure 2.2: Structure of cisplatin | 29 |
| Figure 2.3: Main adducts formed between cisplatin and nucleobases in DNA. (a) interstrand crosslink, (b) I,2-intrastrand dApdG, (c) 1,3-intrastrand, (d) monofunctional adduct | 33 |
| Figure 2.4: Hydrolysis of cisplatin in aqueous solution | 35 |
| Figure 2.5: Structure of transplatin | 36 |
| Figure 2.6: Structure of carboplatin | 38 |
| Figure 2.7: Structure of nedaplatin | 40 |
| Figure 2.8: Structure of oxaliplatin. | 42 |
| Figure 2.9: Structure of JM216 (I) and its active metabolite JM118 (II)..... | 43 |
| Figure 2.10: Structure of lobaplatin. | 44 |
| Figure 2.11: Structure of ZD0473..... | 45 |
| Figure 2.12: Structure of C5-OHP-Cl | 47 |
| Figure 2.13: Summary of the platinum drug development program from carboplatin to ZD0473 | 47 |
| Figure 2.14: Structure of BBR3464 | 54 |
| Figure 2.15: Molecular mechanisms of resistance to platinum drug cisplatin | 61 |
| Figure 2.16: Scheme illustrating the primary biochemical steps of NER. | 68 |

| | |
|--|-----|
| Figure 2.17: Scheme illustrating hypothetical mismatch repair of 1,2-GG-intrastrand cross-link of cisplatin..... | 70 |
| Figure 2.18: Structures of targeted <i>trans</i> -planaraminepalladium(II) complexes and trinuclear Pt-Pd-Pt and Pt-Pt-Pt complexes | 77 |
| Figure 3.1: Schematic synthesis of CH1 | 82 |
| Figure 3.2: Schematic synthesis of TH5 | 83 |
| Figure 3.3: Schematic synthesis of TH6 | 84 |
| Figure 3.4: Schematic synthesis of TH7 | 85 |
| Figure 3.5: Schema for synthesis of TH1 | 88 |
| Figure 3.6: Schema for the synthesis of TH8 | 91 |
| Figure 3.7: Schema for the synthesis of TH14 | 94 |
| Figure 3.8: Typical standards addition graph for platinum | 99 |
| Figure 3.9: Typical standards addition graph for palladium | 102 |
| Figure 3.10: A schematic representation of supercoiled form I DNA, nicked form II DNA and linear form III DNA..... | 122 |
| Figure 3.11: Migration of three forms of plasmid DNA in electric field..... | 122 |
| Figure 3.12: Topological forms of closed circular DNA, negatively supercoiled form I through relaxed circular form to positively supercoiled form I..... | 123 |
| Figure 4.1: Structure of TH5 | 133 |
| Figure 4.2: Structure of TH6 | 133 |
| Figure 4.3: Structure of TH7 | 134 |
| Figure 4.4: Structure of TH1 | 135 |
| Figure 4.5: Structure of TH8 | 135 |
| Figure 4.6: Structure of TH14 | 136 |
| Figure 4.7: IR spectrum of TH5..... | 139 |
| Figure 4.8: IR spectrum of TH6..... | 140 |
| Figure 4.9: IR spectrum of TH7..... | 141 |
| Figure 4.10: IR spectrum of TH1..... | 142 |
| Figure 4.11: IR spectrum of TH8..... | 143 |
| Figure 4.12: IR spectrum of TH14..... | 144 |
| Figure 4.13: Mass spectrum of TH5 | 147 |
| Figure 4.14: Mass spectrum of TH6 | 148 |
| Figure 4.15: Mass spectrum of TH7 | 149 |
| Figure 4.16: Mass spectrum of TH1 | 150 |

| | |
|---|-----|
| Figure 4.17: Mass spectrum of TH8 | 151 |
| Figure 4.18: Mass spectrum of TH14 | 152 |
| Figure 4.19: ¹ H NMR spectrum of TH5..... | 155 |
| Figure 4.20: ¹ H NMR spectrum of TH6..... | 156 |
| Figure 4.21: ¹ H NMR spectrum of TH7..... | 157 |
| Figure 4.22: ¹ H NMR spectrum of TH1..... | 158 |
| Figure 4.23: ¹ H NMR spectrum of TH8..... | 159 |
| Figure 4.24: ¹ H NMR spectrum of TH14..... | 160 |
| Figure 4.25: Molar conductivity for TH5, TH6, TH7, TH1, TH8 and TH14 | 163 |
| Figure 4.26: Cell survival curve for the human ovary cancer cell line A2780 when the cells were treated with increasing concentrations of TH5, TH6, TH7 and cisplatin..... | 166 |
| Figure 4.27: Cell survival curve for the human ovary cancer cell line A2780 ^{cisR} when cells were treated with increasing concentrations of TH5, TH6, TH7 and cisplatin | 168 |
| Figure 4.28: Cell survival curve for the human ovary cancer cell line A2780 ^{ZD0473R} when the cells treated with increasing concentrations of TH5, TH6, TH7 and cisplatin..... | 170 |
| Figure 4.29: Cell survival curve for the human ovary cancer cell line A2780 when the cells were treated with increasing concentrations of TH1, TH8, TH14 and cisplatin | 172 |
| Figure 4.30: Cell survival curve for the human ovary cancer cell line A2780 ^{cisR} when the cells were treated with increasing concentrations of TH1, TH8, TH14 and cisplatin | 174 |
| Figure 4.31: Cell survival curve for the human ovary cancer cell line A2780 ^{ZD0473R} when the cells were treated with increasing concentrations of TH1, TH8, TH14 and cisplatin | 176 |
| Figure 4.32: Pd and Pt cell uptake as nmol Pd or Pt per 2x10 ⁶ cells in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells in 2 h as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin | 180 |
| Figure 4.33: Pd and Pt cell uptake as nmol Pd or Pt per 2x10 ⁶ cells in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells in 4 h as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin. | 182 |

| | |
|---|-----|
| Figure 4.34: Pd and Pt cell uptake as nmol Pd or Pt per 2×10^6 cells in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells in 24 h as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin. | 184 |
| Figure 4.35: Pd and Pt cell uptake as nmol Pd or Pt per 2×10^6 cells in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells in 72 h as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin | 186 |
| Figure 4.36: Levels of Pd and Pt binding with DNA in 2 h in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin. | 189 |
| Figure 4.37: Levels of Pd and Pt binding with DNA in 4 h in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin. | 191 |
| Figure 4.38: Levels of Pd and Pt binding with DNA in 24 h in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin | 193 |
| Figure 4.39: Levels of Pd and Pt binding with DNA in 72 h in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin | 195 |
| Figure 4.40: Electrophoretograms applying to the interaction of ssDNA with increasing concentrations of TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin | 196 |
| Figure 4.41: Electrophoretograms applying to the interaction of pBR322 plasmid DNA with increasing concentrations of TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin..... | 198 |
| Figure 4.42: Electrophoretograms applying to the incubated mixtures of pBR322 plasmid DNA and varying concentrations of compounds: TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin followed by their digestion with BamH1 | 201 |

List of Tables

| | |
|---|-----|
| Table 1.1: Stage grouping for primary carcinoma of the ovary according to International Federation of Gynecology and Oncology | 16 |
| Table 1.2: Average helix parameters for the major DNA conformations | 22 |
| Table 2.1: Chemical and biological properties of dinuclear and trinuclear platinum complexes under evaluation as potential anticancer agent | 51 |
| Table 3.1: Furnace operating conditions for the determination of platinum | 97 |
| Table 3.2: Instrument parameters for the determination of platinum | 98 |
| Table 3.3: Sampler parameters used in AAS to determine platinum | 99 |
| Table 3.4: Furnace operating conditions for the determination of palladium | 100 |
| Table 3.5: Instrument parameters for the determination of palladium | 101 |
| Table 3.6: Sampler parameters used in AAS to determine palladium | 102 |
| Table 3.7: Constituents of the medium (FCS/RPMI 1640) | 110 |
| Table 4.1: Elemental compositions of CH1, TH5, TH6, and TH7 | 134 |
| Table 4.2: Elemental composition for TH1, TH8, and TH14 | 137 |
| Table 4.3: Prominent IR spectral bands observed for TH5, TH6 and TH7 | 145 |
| Table 4.4: Prominent IR spectral bands observed in TH1, TH8 and TH14 | 146 |
| Table 4.5: The Mass spectra of TH5, TH6 and TH7 where the number in parentheses after each m/z value indicates the relative intensity | 153 |
| Table 4.6: The Mass spectra of TH1, TH8 and TH14 where the number in parentheses after each m/z value indicates the relative intensity | 154 |
| Table 4.7: Prominent peaks observed in ¹ H NMR spectra of TH5, TH6 and TH7 ... | 161 |
| Table 4.8: Prominent peaks observed in ¹ H NMR spectra of TH1, TH8 and TH14 . | 162 |
| Table 4.9: Molar conductivity values for TH5, TH6, TH7, TH1, TH8 and TH14 | 163 |
| Table 4.10: The cell survival rate as a percentage of the control for the human ovary cancer cell line A2780, when the cells were treated with TH5, TH6, TH7 and cisplatin | 165 |
| Table 4.11: The cell survival rate as a percentage of the control for the human ovary cancer cell line A2780 ^{cisR} , when the cells were treated with TH5, TH6, TH7 and cisplatin | 167 |

| | |
|---|-----|
| Table 4.12: The cell survival rate as a percentage of the control for the human ovary cancer cell line A2780 ^{ZD0473R} , when the cells were treated with TH5, TH6, TH7 and cisplatin | 169 |
| Table 4.13: The cell survival rate as a percentage of the control for the human ovary cancer cell line A2780, when the cells were treated with TH1, TH8, TH14 and cisplatin | 171 |
| Table 4.14: The cell survival rate as a percentage of the control for the human ovary cancer cell line A2780 ^{cisR} , when the cells were treated with TH1, TH8, TH14 and cisplatin..... | 173 |
| Table 4.15: The cell survival rate as a percentage of the control for the human ovary cancer cell line A2780 ^{ZD0473R} , when the cells were treated with TH1, TH8, TH14 and cisplatin | 175 |
| Table 4.16: Lists the IC ₅₀ values and resistance factors (RF) of all of the compounds TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin..... | 177 |
| Table 4.17: Pd and Pt accumulation in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells in 2 h as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin.. | 179 |
| Table 4.18: Pd and Pt accumulation in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells in 4 h as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin. | 181 |
| Table 4.19: Pd and Pt accumulation in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells in 24 h as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin.. | 183 |
| Table 4.20: Pd and Pt accumulation in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells in 72 h as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin.. | 185 |
| Table 4.21: Levels of Pd and Pt binding with DNA in 2 h in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin. | 188 |
| Table 4.22: Levels of Pd and Pt binding with DNA in 4 h in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin. | 190 |
| Table 4.23: Levels of Pd and Pt binding with DNA in 24 h in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin. | 192 |
| Table 4.24: Levels of Pd and Pt binding with DNA in 72 h in A2780, A2780 ^{cisR} and A2780 ^{ZD0473R} cells as applied to TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin. | 194 |

| | |
|---|-----|
| Table 4.25: Bands observed after BamH1 digestion of incubated mixtures of TH5, TH6, TH7, TH1, TH8, TH14 and cisplatin with pBR322 plasmid DNA | 203 |
| Table 4.26: The retention times of the main peaks with the detector set at $\lambda = 260$ nm for the mixtures and the components..... | 205 |
| Table4.27: Pt or Pd: G binding ratios of the major peaks in the incubated mixtures of TH5, TH6, TH7, TH1, TH8 and TH14 with guanine..... | 206 |